'Visiongain Report Predicts Emergence of Indian Pharma Giant' says visiongain report.

SAN FRANCISCO & LONDON -- By virtue of its huge population the Indian pharmaceutical market has a huge potential but due to a lack of IP rights has yet been realised. However, a new patent law in compliance with WTO TRIPS agreement, coming into effect on Jan1st 2006, has the possibility of transforming the Indian pharmaceutical market. Under this new law multinational companies can enter the market without the concern that local Indian companies will copy their valuable drugs and sell them cheaply as generics, which has been the situation so far. However, the success of the new patent law depends entirely on the degree the Indian government is willing to implement the law and the resources they will devote to its enforcement.

The Indian pharmaceutical market is the 15th largest in the world pharmaceutical market by sales, 4th by volume and is currently valued at $4.98 billion. However, it has been largely avoided by the leading pharmaceutical companies due to lack of adequate IP protection, consequently the Indian market has been dominated by cheap generic drugs.

Not only are international multinational companies gearing up to fully enter the Indian market, but large Indian companies are becoming increasingly adept at penetrating the large international with high volume generic drugs. Also, these companies are making high investments into R&D.

As Indian pharma struggles to adapt to product patents, visiongain, however, is predicting the emergence of a ground breaking first says visiongain pharmaceutical market analyst Tristan Heath; "The development of an internationally competitive Indian R&D based pharmaceutical company which will be a major economic step for India."

Visiongain's report - The Indian Pharmaceutical Market, 2006-2011 - assess the market, analyses the key companies involved and predicts the changes that are likely to be seen in the next five years in this fast growing market. Assessment of the structures shaping the market, particularly the system of patents illuminate a previously avoided market, and highlight the potential already seen by the world's leading pharmaceutical companies.

Notes for editors: To receive your complimentary overview of - The Indian Pharmaceutical Market, 2006-2011 - Please send an email to Sara Peerun [e-mail], telephone Sara on [phone] or see www.visiongainintelligence.com. Please include your full name, title of publication, contact telephone number, email, and details of where you saw this release. Upon receipt of this information, an overview will be emailed to you.

Companies mentioned in this report include:

Abbott, ALKEM, Allen SpA, Apotex, Argenta, AstraZeneca, Aurex Generics, Aurobindo Pharma, Avecia, Pharmaceuticals, Baxter International, Biocon, Boots International, Boots Piramal, BYK Gulden, Cipla, Clonmel Healthcare, CP Pharmaceuticals, Cynamid, Divis Laboratories, Docpharma, Dr Reddy's Laboratories, Eli Lilly, Eon

Gene Arrays, Glenmark Pharmaceuticals, GSK, Interpharma, Iracot, IVAX, Konec, Lupin, Malladi Drugs and Pharmaceuticals, Matrix Laboratories, MCHEM Pharma, Merck & Co. , Milpharm, Momenta, Morton Grove, Nicholas Piramal, Novartis, Novo Nordisk, Novus Fine Chemicals, Orchid Chemicals, Pfizer, Pharmascience Group, Ranbaxy Laboratories, Ratiopharm, Reckitt Benckiser, Regent Drugs, Rhone-Poulenc, Sandoz, Sanofi-Aventis, Shasun Chemicals and Drugs, Stada, Sun Pharmaceuticals, Terapia, Teva, Trigenerics Therapeutics, Watson, Whyte Group, Wockhardt Ltd, Zydus Cadila and Zydus BYK Healthcare.

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Pharmaceutical, Telecoms and Defence sectors. 'Visiongain has a global client base, with offices in London and San Francisco.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

For information on visiongain, please visit www.visiongainintelligence.com